SCHEMBL4258381

SCHEMBL4258381

Cc1c(-c2csc(-c3ccccc3C(F)(F)F)n2)ccc2c1NC(=O)CO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 2/20 0.47
PIM1 P11309 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 6/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
EIF4E P06730 1/20 0.40
VCP P55072 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
TRPA1 O75762 2/20 0.35
MAP4K1 Q92918 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264485 0.89 NR3C2 (0.49) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4263153 0.89 NR3C2 (0.41) NR3C2PIM1POLBMAPTALDH1A1
SCHEMBL4260398 0.85 NR3C2 (0.56) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4267847 0.82 NR3C2 (0.48) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4258380 0.82 POLB (0.51) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4267726 0.81 NR3C2 (0.46) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4267313 0.80 MAPT (0.62) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4273018 0.80 MAPT (0.60) NR3C2POLBMAPTALDH1A1SMN1; SMN2
SCHEMBL4265368 0.80 NR3C2 (0.48) NR3C2PIM1POLBMAPTALDH1A1
SCHEMBL4258355 0.79 CYP17A1 (0.51) NR3C2POLBMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885PIM1 4766/4885POLB 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.